Banner Health

The Translational Genomics Research Institute

Other

The General Hospital Corporation

The Schepens Eye Research Institute, Inc.

Banner Health Systems, Inc.

Eric M Reiman

Kewei Chen

Joseph F Arboleda-Velasquez

Dietrich A Stephan

Andreas Papassotiropoulos

Yakeel T Quiroz

Francisco Lopera

Jennifer Webster

Matt Huentelman

Christopher B Heward

Methods and compositions for preventing or treating cognitive decline associated with dementia and/or mild cognitive impairment and/or neurodegeneration using antibodies, peptides, fusion proteins, or genome editing systems that modulate HSPG/heparin binding affinities of ApoE.

Anti-ApoE antibodies and polynucleotides thereof

A method is disclosed to acquire imaging and non-imaging datasets from like objects. A linkage is found using a partial least squares (PLS) technique between imaging and non-imaging datasets. The linkage is then reduced to an expression of a single numerical assessment. The single numerical assessment is then used as an objective, quantified assessment of the differences and similarities between the objects. The data each dataset can be aspects of performance, physical characteristics, or measurements of appearance.

Methodologies linking patterns from multi-modality datasets

Systems and methods for evaluating prospective treatments for progressive brain disorders like Alzheimer's disease and the progressive effects of aging involve the use of an imaging device communicatively coupled to a computing device. The imaging device may takes a plurality of brain imaging measurements from each of a plurality of human subjects who are divided into a treated group and an untreated group based on various subject data including whether the subjects carry certain alleles of genes known to increase the risk of developing the brain disorder at issue. The computing device receives the brain imaging measurements from the imaging device and applies an advanced processing method that permits enhanced computational efficiency when calculating rates of change for the two groups and determining whether any calculated difference between the rates is statistically significant.

Accelerated evaluation of treatments to prevent clinical onset of neurodegenerative diseases

Accelerated evaluation of treatments to prevent clinical onset of alzheimer's disease

This application discloses SNPs capable of predicting increased or decreased risk of developing late onset Alzheimer's disease.

Markers associated with Alzheimer'S disease

The present disclosure relates to genetic markers and methods of diagnosing and screening for late-onset Alzheimer's disease (LOAD). As such, the disclosure encompasses a whole-genome association analysis of single nucleotide polymorphisms (SNPs) of which a number are located within the GRB2-associated binding protein 2 (GAB2) gene as well as other markers associated with other genes. The disclosure identifies two novel haplotypes within the GAB2 gene, i.e., a LOAD risk-enhancing and a LOAD risk-decreasing haplotype. These haplotypes modify LOAD risk differentially in combination with APOE alleles. Further encompassed are therapeutic methods and agents of decreasing the deterioration of cells associated with LOAD.

Methods of diagnosing alzheimer's disease and markers identified by set association

A method of screening pharmaceutical drugs, gene therapies, vaccines, dietary supplements, behavioral and environmental therapies and other clinical treatments for potential efficacy in the treatment of Alzheimer's disease in humans. The method includes selecting transgenic mice that are genetically altered for Alzheimer's disease and using measurement and/or imaging techniques to determine the activity level of the posterior cingulate region of the brains of the mice after treatment. Based on these measurements and comparisons to a control group, the effectiveness of the treatment in arresting or reversing Alzheimer's disease in mice can be determined, and the treatment can be identified as a promising candidate for human trials.

Growing community of inventors

Scottsdale, AZ, United States of America

Eric M Reiman